Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Leroy Hood-led Dx firm gains $30m

This article was originally published in Clinica

Executive Summary

A newly launched Seattle, Washington firm, which will specialise in genomic and proteomic technologies for personalised and preventative diagnostics, has raised $30m in its first round of financing. Investors in Integrated Diagnostics include InterWest Partners, which led the round; The Wellcome Trust and dievini Hopp BioTech. The founder of Integrated Diagnostics is Leroy Hood, inventor of the DNA sequencer and current president of The Institute of Biology. The company will have access to Dr Hood's research on protein blood markers which can give an indication on the physiological state of the body's 50 major organs. By monitoring concentrations of these proteins in the blood, disruptions in healthy function can be detected and traced back to the diseased organ, according to Integrated Diagnostics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel